Financial Results
#FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery
FY/25 – Strong organic revenue and excellent Core EPS growth; REJUVENATE phase spurs profitable growth, drives stronger balance sheet, and creates significant value.
- Group revenue1 at €22,554 million with organic growth of 7%1,2 reflecting the consistent execution across Fresenius Kabi and Fresenius Helios.
- Group EBIT1 at €2,595 million with 6%3 growth in constant currency driven in particular by Fresenius Kabi’s Growth Vectors and the strong performance of Fresenius Helios in Spain; Group EBIT margin1 at 11.5% despite significant headwinds.
- Core EPS1,4 increased by 12%3 in constant currency to €2.87 based on strong operating results and significantly decreased interest expense.
- Structural EBIT margin ambition increased for Fresenius Kabi to 17 to 19% (previously 16 to 18%)
Constant currency Core EPS growth1,4 established as new guidance metric is expected to be in the range of 5 to 10% in FY/26; organic revenue growth2 projected to be in the range of 4 to 7% in FY/26. - Net debt/EBITDA ratio improved by 30 bp to 2.7x1,5, well within the self-imposed target corridor of 2.5 to 3.0x; driven by cash flow delivery leading to significant debt reduction.
- Dividend proposal of €1.05 per share; year-on-year increase of 5%, in line with the Company's dividend payout ratio of 30 to 40%.
Selected Key Figures FY/2025
GROUP REVENUE 1
€ 22554 m
+ 7% 2
FY/24: €21,526 m
GROUP EBIT 1
€ 2595 m
+6% 3
FY/24: €2,489 m
NET INCOME 1, 4
€ 1619 m
+12% 3
FY/24: €1,461 m
EPS 1, 4
€ 2.87
+12% 3
FY/24: €2.59
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Growth rate at constant currency (cc) and adjusted for Argentina hyperinflation
4 Excluding Fresenius Medical Care
Revenue by business segment
| € in millions | FY/25 | FY/24 | Growth at actual rates | Growth at constant rates1 | Organic growth2 | Acquisitions/Divestitures | % of total revenue |
|---|---|---|---|---|---|---|---|
Fresenius Kabi | 8,612 | 8,414 | 2% | 6%1 | 7%2 | -1% | 38% |
Fresenius Helios | 13,550 | 12,739 | 6% | 7% | 7% | 0% | 60% |
Total | 22,554 | 21,526 | 5% | 6% | 7% | -1% | 100%3 |
-
1 Growth rate adjusted for Argentina hyperinflation
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Remaining 2% Corporate/Other revenue
Before special items